
JAVIER
PUENTE VÁZQUEZ
Profesor asociado
Publications (175) JAVIER PUENTE VÁZQUEZ publications
2025
-
Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer
Cancers, Vol. 17, Núm. 1
2024
-
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45
-
CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis
Cancer Letters, Vol. 588
-
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer
Lung Cancer, Vol. 192
-
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
European Urology, Vol. 86, Núm. 1, pp. 4-9
-
Correlation of safety and efficacy of atezolizumab therapy across indications
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 11
-
Criteria and indicators to evaluate quality of care in genitourinary tumour boards
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1639-1646
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Clinical and Translational Oncology, Vol. 26, Núm. 6, pp. 1532-1538
-
Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study
Clinical and Translational Oncology
-
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
ESMO Open, Vol. 9, Núm. 9
-
Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma
Clinical Genitourinary Cancer
-
Molecularly Defined Renal Carcinomas
Kidney Cancer, Vol. 8, Núm. 1, pp. 31-44
-
Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer
Actas Urologicas Espanolas, Vol. 48, Núm. 10, pp. 703-717
-
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441
-
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
Cancers, Vol. 16, Núm. 14
-
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
European urology oncology, Vol. 7, Núm. 3, pp. 447-455
-
Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Clinical and Translational Oncology
2023
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer
Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126